Business Context and Reporting Period
Propanc Biopharma, Inc. filed this Form 8-K on July 13, 2018, reporting the entry into a Material Definitive Agreement. The Company, incorporated in Delaware with principal offices in Australia, entered into a securities purchase agreement with Eagle Equities, LLC. The transaction closed on July 16, 2018.
Key Financial Metrics and Transaction Details
- Principal Amount: $75,000.00
- Net Proceeds: $71,250.00 (after a $3,750.00 deduction for legal expenses)
- Instrument Type: 8% Convertible Promissory Note
- Maturity Date: July 13, 2019
- Interest Rate: 8% per annum (payable in shares upon conversion)
- Use of Proceeds: General working capital
Material Changes and Terms
The filing details the issuance of debt that may convert into equity, representing a material change in the Company's capital structure. Key terms include:
- Conversion Price: 60% of the lowest closing bid price of the prior ten trading days. This discount deepens to 50% if trading is restricted by the Depository Trust Company.
- Prepayment Penalties: Significant premiums apply for early repayment (130% to 150% of face value plus accrued interest depending on the timing).
- Default Interest: Increases to 24% per annum upon an event of default.
- Liquidated Damages: $250 per day for delays in issuing shares (days 4-9), increasing to $500 per day thereafter.
- Principal Increase Triggers: The principal amount increases by 20% if the stock loses its bid price, and by 50% if the stock is delisted, trading is suspended for over ten days, or reporting obligations are failed.
Guidance, Risks, and Contingencies
The filing does not provide forward-looking financial guidance or management commentary regarding future performance. However, it outlines significant financial risks and contingencies associated with the Note:
- Dilution Risk: The 40% conversion discount and potential for increased principal amounts upon default or delisting create substantial dilution risk for existing shareholders.
- Liquidity Risk: The Company must maintain a reserve of shares at least four times the number issuable upon conversion for 60 days, or face an increased conversion discount.
- Compliance Risk: Failure to file periodic reports or maintain listing status triggers severe financial penalties, including a 50% increase in the principal debt obligation.
- Change of Control: In the event of a merger or asset transfer, the holder may demand redemption at 150% of the principal plus accrued interest.
Investor Verification Checklist
- Verify the current trading status and bid price of Propanc Biopharma, Inc. common stock on the OTC Markets Group to assess the immediate conversion price.
- Confirm the Company's compliance with SEC reporting obligations to avoid the 50% principal increase penalty.
- Review the Company's authorized share count to ensure it can meet the 4x reserve requirement for conversion shares.
- Monitor the Company's cash position to determine if it can service the 8% interest or if it will be forced to issue shares, accelerating dilution.
- Check for any subsequent filings regarding the prepayment of the Note or additional debt issuances.